Skip to main content

Table 1 Summary of experimental groups of Aotus monkeys immunized against HBsAg

From: Immune Response to a Hepatitis B DNA Vaccine in Aotus Monkeys: A Comparison of Vaccine Formulation, Route, and Method of Administration

Group Gender Immunogen a Formulation b Delivery Route and Method c
1 1 F, 3 M DNA Saline IM, needle and syringe, 4 sites
2 1 F, 3 M DNA Saline IM, Biojector, 4 sites
3 3 F, 1 M DNA Liposome IM, needle and syringe, 4 sites
4 1 F, 3 M DNA Liposome IM, Biojector, 4 sites
5 2 F, 2 M DNA Saline ID, needle and syringe, 4 sites
6 1 F, 3 M DNA Saline IM, Biojector and ID, needle and syringe, 2 sites each
7 4M DNA E. coli DNA IM, needle and syringe, 4 sites
8 3 F, 1 M DNA E. coli DNA ID, needle and syringe, 4 sites
9 3 F, 1 M Engerix-B N/A IM, needle and syringe, 1 site
  1. aDNA (pCMVA-S, 400 µg) was given at 0 and 8 weeks to all monkeys except group 9. All monkeys received Engerix-B (10 µg HBsAg + alum) at 16 weeks.
  2. bDNA was dissolved in saline or was complexed with a cationic liposome (CellFECTIN) at a 10:1 w/w DNA:lipid ratio. DNA formulated with E.coli DNA was dissolved in saline. N/A = not applicable.
  3. cSites for IM were bilateral deltoid and quadriceps. Sites for ID were over lower back.